$39.78
0.33% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

BridgeBio Pharma Inc Stock price

$39.78
+6.52 19.60% 1M
+12.29 44.71% 6M
+12.34 44.97% YTD
+10.78 37.17% 1Y
+8.67 27.87% 5Y
+12.23 44.39% 10Y
+12.23 44.39% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.13 0.33%
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

Key metrics

Market capitalization $7.53b
Enterprise Value $9.33b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 73.25
P/S ratio (TTM) P/S ratio 59.09
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -41.71%
Revenue (TTM) Revenue $127.42m
EBIT (operating result TTM) EBIT $-684.91m
Free Cash Flow (TTM) Free Cash Flow $-509.44m
Cash position $540.60m
EPS (TTM) EPS $-3.53
P/E forward negative
P/S forward 17.88
EV/Sales forward 22.16
Short interest 19.52%
Show more

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a BridgeBio Pharma Inc forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
84%
Hold
16%

Financial data from BridgeBio Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
127 127
42% 42%
100%
- Direct Costs 5.92 5.92
147% 147%
5%
122 122
44% 44%
95%
- Selling and Administrative Expenses 329 329
78% 78%
259%
- Research and Development Expense 477 477
5% 5%
374%
-679 -679
46% 46%
-533%
- Depreciation and Amortization 5.76 5.76
11% 11%
5%
EBIT (Operating Income) EBIT -685 -685
45% 45%
-538%
Net Profit -668 -668
24% 24%
-524%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Positive
Seeking Alpha
10 days ago
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, fa...
Neutral
GlobeNewsWire
12 days ago
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET.
Neutral
GlobeNewsWire
25 days ago
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Neil Kumar
Employees 728
Founded 2015
Website bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today